The initial hypothesis was that treatment responses to pembrolizumab could be determined by two factors: (i) the basal level of expression of PDL1 in residual pathological PC, and (ii) the characteristics of the patients’ immune system at enrollment and/or potential modulations induced by the treatment. This evidence concerns the gene CD274 and pachyonychia congenita.